PTGDR | OmnibusX

Name	Number of supported studies	Average coverage
natural killer cell	29 studies	29% ± 9%	Explore
CD16-negative, CD56-bright natural killer cell, human	15 studies	33% ± 12%	Explore
CD16-positive, CD56-dim natural killer cell, human	15 studies	37% ± 11%	Explore
mature NK T cell	8 studies	27% ± 9%	Explore
CD8-positive, alpha-beta T cell	5 studies	21% ± 3%	Explore
gamma-delta T cell	5 studies	19% ± 3%	Explore
effector memory CD8-positive, alpha-beta T cell	4 studies	23% ± 6%	Explore
mucosal invariant T cell	4 studies	19% ± 3%	Explore
lymphocyte	3 studies	29% ± 6%	Explore
innate lymphoid cell	3 studies	32% ± 10%	Explore
group 3 innate lymphoid cell	3 studies	18% ± 1%	Explore
effector memory CD8-positive, alpha-beta T cell, terminally differentiated	3 studies	22% ± 3%	Explore

sc-RNAseq data

Insufficient scRNA-seq data for expression of PTGDR at tissue level.

Tissue	GTEx Coverage	GTEx Average TPM	GTEx Number of samples	TCGA Coverage	TCGA Average TPM	TCGA Number of samples
breast	97%	181.80	447 / 459	33%	1.11	374 / 1118
lung	98%	246.58	567 / 578	23%	0.44	271 / 1155
thymus	98%	174.97	643 / 653	23%	0.57	139 / 605
intestine	82%	422.98	789 / 966	36%	3.55	192 / 527
uterus	98%	229.52	166 / 170	14%	0.30	64 / 459
kidney	62%	64.66	55 / 89	48%	1.11	431 / 901
spleen	100%	812.04	241 / 241	0%	0	0 / 0
bladder	81%	130.76	17 / 21	18%	0.93	91 / 504
adipose	98%	259.10	1183 / 1204	0%	0	0 / 0
prostate	89%	132.59	217 / 245	7%	0.11	35 / 502
stomach	65%	59.90	233 / 359	28%	1.69	81 / 286
heart	87%	106.10	747 / 861	0%	0	0 / 0
blood vessel	76%	116.48	1021 / 1335	0%	0	0 / 0
peripheral blood	76%	291.26	708 / 929	0%	0	0 / 0
liver	69%	60.26	157 / 226	6%	0.14	26 / 406
skin	61%	50.59	1099 / 1809	11%	0.19	52 / 472
esophagus	60%	56.40	869 / 1445	10%	0.17	18 / 183
ovary	65%	95.73	117 / 180	3%	0.04	14 / 430
pancreas	17%	11.21	57 / 328	31%	0.59	56 / 178
adrenal gland	29%	52.73	76 / 258	7%	0.20	16 / 230
lymph node	0%	0	0 / 0	34%	0.86	10 / 29
brain	22%	18.43	572 / 2642	4%	0.10	29 / 705
tonsil	0%	0	0 / 0	20%	0.30	9 / 45
muscle	19%	11.39	150 / 803	0%	0	0 / 0
eye	0%	0	0 / 0	1%	0.01	1 / 80
abdomen	0%	0	0 / 0	0%	0	0 / 0
bone marrow	0%	0	0 / 0	0%	0	0 / 0
diaphragm	0%	0	0 / 0	0%	0	0 / 0
gingiva	0%	0	0 / 0	0%	0	0 / 0
nasal cavity	0%	0	0 / 0	0%	0	0 / 0
nasopharynx	0%	0	0 / 0	0%	0	0 / 0
nose	0%	0	0 / 0	0%	0	0 / 0
placenta	0%	0	0 / 0	0%	0	0 / 0
spinal column	0%	0	0 / 0	0%	0	0 / 0
ureter	0%	0	0 / 0	0%	0	0 / 1

GO_0043303	Biological process	mast cell degranulation
GO_0071799	Biological process	cellular response to prostaglandin D stimulus
GO_0007186	Biological process	G protein-coupled receptor signaling pathway
GO_0030238	Biological process	male sex determination
GO_0007204	Biological process	positive regulation of cytosolic calcium ion concentration
GO_0006954	Biological process	inflammatory response
GO_0046085	Biological process	adenosine metabolic process
GO_0030431	Biological process	sleep
GO_0016020	Cellular component	membrane
GO_0005886	Cellular component	plasma membrane
GO_0004956	Molecular function	prostaglandin D receptor activity
GO_0005515	Molecular function	protein binding
GO_0001785	Molecular function	prostaglandin J receptor activity

Gene name	PTGDR
Protein name	Prostaglandin D2 receptor (PGD receptor) (PGD2 receptor) (Prostanoid DP receptor)
Synonyms
Description	FUNCTION: Receptor for prostaglandin D2 (PGD2). The activity of this receptor is mainly mediated by G(s) proteins that stimulate adenylate cyclase, resulting in an elevation of intracellular cAMP. A mobilization of calcium is also observed, but without formation of inositol 1,4,5-trisphosphate (By similarity). Involved in PLA2G3-dependent maturation of mast cells. PLA2G3 is secreted by immature mast cells and acts on nearby fibroblasts upstream to PTDGS to synthesize PGD2, which in turn promotes mast cell maturation and degranulation via PTGDR (By similarity). .
Accessions	ENST00000306051.3 [Q13258-1] ENST00000553372.1 [Q13258-2] Q13258

PTGDR report